Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metformin-induced lactic acidosis

作者: K Toyama , A Yonezawa , S Masuda , R Osawa , M Hosokawa

DOI: 10.1111/J.1476-5381.2012.01853.X

关键词:

摘要: BACKGROUNDS AND PURPOSE Lactic acidosis is a fatal adverse effect of metformin, but the risk factor remains unclear. Multidrug and toxin extrusion 1 (MATE1) expressed in luminal membrane kidney liver. MATE1 was revealed to be responsible for tubular biliary secretion metformin. Therefore, some MATE polymorphisms, that cause it function abnormally, are hypothesized induce lactic acidosis. The purpose this study clarify association between dysfunction metformin-induced acidosis. EXPERIMENTAL APPROACH Blood lactate, pH bicarbonate ion (HCO3-) levels were evaluated during continuous administration 3 mg·mL−1 metformin drinking water using Mate1 knockout (−/−), heterozygous (+/−) wild-type (+/+) mice. To determine tissue accumulation mice given 400 mg·kg−1 orally. Furthermore, blood lactate data obtained from diabetic patients metformin. KEY RESULTS Seven days after water, significantly higher lower HCO3- observed Mate1−/− mice, not Mate1+/− affected with variant (MATE1-L125F, MATE1-G64D, MATE2-K-G211V). Sixty minutes (400 mg·kg−1, p.o.) hepatic concentration markedly than Mate1+/+ mice. CONCLUSION IMPLICATIONS MATE1 caused marked elevation liver led acidosis, suggesting homozygous could one factors

参考文章(27)
SLCO1B1 variants and statin-induced myopathy--a genomewide study The New England Journal of Medicine. ,vol. 359, pp. 789- 799 ,(2008) , 10.1056/NEJMOA0801936
Brian L. Pearlman, Andrew Z. Fenves, Michael Emmett, Metformin-associated lactic acidosis. The American Journal of Medicine. ,vol. 101, pp. 109- 110 ,(1996) , 10.1016/S0002-9343(97)89422-3
Moto Kajiwara, Tomohiro Terada, Ken Ogasawara, Junko Iwano, Toshiya Katsura, Atsushi Fukatsu, Toshio Doi, Ken-ichi Inui, Identification of multidrug and toxin extrusion (MATE1 and MATE2-K) variants with complete loss of transport activity. Journal of Human Genetics. ,vol. 54, pp. 40- 46 ,(2009) , 10.1038/JHG.2008.1
A. F. Al-Jebawi, M. N. Lassman, N. N. Abourizk, Lactic Acidosis With Therapeutic Metformin Blood Level in a Low-Risk Diabetic Patient Diabetes Care. ,vol. 21, pp. 1364- 1365 ,(1998) , 10.2337/DIACARE.21.8.1364
Garry G Graham, Jeroen Punt, Manit Arora, Richard O Day, Matthew P Doogue, Janna K Duong, Timothy J Furlong, Jerry R Greenfield, Louise C Greenup, Carl M Kirkpatrick, John E Ray, Peter Timmins, Kenneth M Williams, Clinical pharmacokinetics of metformin. Clinical Pharmacokinectics. ,vol. 30, pp. 359- 371 ,(1996) , 10.2165/00003088-199630050-00003
M. Otsuka, T. Matsumoto, R. Morimoto, S. Arioka, H. Omote, Y. Moriyama, A human transporter protein that mediates the final excretion step for toxic organic cations Proceedings of the National Academy of Sciences of the United States of America. ,vol. 102, pp. 17923- 17928 ,(2005) , 10.1073/PNAS.0506483102
Yuko Tanihara, Satohiro Masuda, Tomoko Sato, Toshiya Katsura, Osamu Ogawa, Ken-ichi Inui, Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H+-organic cation antiporters Biochemical Pharmacology. ,vol. 74, pp. 359- 371 ,(2007) , 10.1016/J.BCP.2007.04.010
Naoko Kimura, Satohiro Masuda, Yuko Tanihara, Harumasa Ueo, Masahiro Okuda, Toshiya Katsura, Ken-ichi Inui, Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metabolism and Pharmacokinetics. ,vol. 20, pp. 379- 386 ,(2005) , 10.2133/DMPK.20.379